title: Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia.
authors: W
authors: W
authors: Meekison
authors: M
authors: M
authors: Hutcheon
authors: R
authors: R
authors: Guasparini
authors: M
authors: M
authors: Arnott
authors: D
authors: D
authors: Scheifele
authors: M
authors: M
authors: Grace
authors: G
authors: G
authors: Humphreys
authors: L
authors: L
authors: Barreto
mesh_terms: D001428:Bacterial Vaccines / Q000009:adverse effects*; D001955:British Columbia; D002675:Child, Preschool; D004168:Diphtheria Toxoid / Q000009:adverse effects*; D005260:Female; D006192:Haemophilus Infections / Q000517:prevention & control*; D018073:Haemophilus Vaccines; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D011358:Product Surveillance, Postmarketing
chemical_list: D001428:Bacterial Vaccines; D004168:Diphtheria Toxoid; D018073:Haemophilus Vaccines; C052180:Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate